Le Lézard
Classified in: Health, Science and technology
Subject: Stock Sale/Buyback

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)


Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today reported that on December 16, 2021, the company granted non-statutory stock options to purchase an aggregate of 42,850 shares of the company's common stock to 14 newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement to such employees' acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation.

The stock options have an exercise price of $35.04 per share, equal to the closing price of Schrödinger's common stock on December 16, 2021. Each stock option has a ten-year term and vests over four years, with 25 percent of the shares underlying the option vesting when the employee completes 12 months of continuous service measured from the employment start date and the balance of the shares vesting in a series of successive equal monthly installments of 1/48 of the original number of shares upon the employee's completion of each additional month of service over the 36 months following the first anniversary of the employment start date. The inducement grants are subject to the terms and conditions of award agreements covering the grants and the company's 2021 Inducement Equity Incentive Plan.

About Schrödinger

Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger's multidisciplinary drug discovery team also leverages the software platform to advance collaborative programs and its own pipeline of novel therapeutics to address unmet medical needs.

Founded in 1990, Schrödinger has over 500 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com, follow us on LinkedIn and Twitter, or visit our blog, Extrapolations.com.


These press releases may also interest you

at 06:34
Trip.com Group has announced record bookings in Abu Dhabi, exceeding 57,000 room nights over the past 12 months. Following a strategic partnership signed at the Arabian Travel Market last year, Trip.com Group's comprehensive portfolio of travel...

at 06:31
Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annual...

at 06:30
Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular...

at 06:30
Viavi Solutions Inc. (VIAVI)  today announced it has participated in the 2024 RIC Forum, March 26-28, in Dallas, Texas. The company contributed its TeraVM RIC Test and TM500 Network Tester to multiple demonstrations, building on collaborations at MWC...

at 06:30
LightInTheBox Holding Co., Ltd. ("LightInTheBox" or the "Company"), an apparel e-commerce retailer that ships products to consumers worldwide, today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31,...

at 06:30
Full-year 2023 revenue of $20.4 million reflects a decrease from 2022 revenue of $7.3 due to a managed decrease in B2C and strategic milestone revenue as the core B2B2C revenue increased.2023 B2B2C, employers and health plans recurring revenues...



News published on and distributed by: